Mitochon Pharmaceuticals, Inc. develops drugs for mitochondria, an organelle found in large numbers in most cells, in which the biochemical processes of respiration and energy production occur. The company offers development programs on neurodegenerative and neuromuscular diseases including, huntingtin’s disease, multiple sclerosis/optic neuritis, wolfram syndrome, epilepsy, traumatic brain injury (TBI), duchenne muscular dystrophy (DMD), alzheimer’s disease, and parkinson disease. Mitochon Pharmaceuticals, Inc. was incorporated in 2014 and is based in Blue Bell, Pennsylvania.
Mitochon Pharmaceuticals, Inc. develops drugs for mitochondria, an organelle found in large numbers in most cells, in which the biochemical processes of respiration and energy production occur. The company offers development programs on neurodegenerative and neuromuscular diseases including, huntingtin’s disease, multiple sclerosis/optic neuritis, wolfram syndrome, epilepsy, traumatic brain injury (TBI), duchenne muscular dystrophy (DMD), alzheimer’s disease, and parkinson disease. Mitochon Pharmaceuticals, Inc. was incorporated in 2014 and is based in Blue Bell, Pennsylvania.